sildosin 2 mg versus sildosin 4 mg in premature ejaculation: a prospective study

Evaluation of the efficacy and safety of sildosin 2 mg versus sildosin 4 mg in premature ejaculation: a prospective study - alpha blockers and premature ejaculation

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038663

Enrollment

100

Registered

2019-11-23

Start date

2019-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urology

Interventions

group 1 will receive sildosin 4 mg for 2 months group 1 will receive sildosin 2 mg for 2 months

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: All males who suffer from premature ejaculation

Exclusion criteria

Exclusion criteria: All males who suffer from ED or prostatitis or receive medications that affect ejaculatory function

Design outcomes

Primary

Measure	Time frame
safety and efficacy	—

Secondary

Measure	Time frame
safety and efficacy	—

Countries

Africa

Contacts

Public Contactsameh gamalel din

Kasr AlAiny faculty of medicine Andrology & STDs

samehfayek@hotmail.com01227109309

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026